瑞舒伐他汀,临床注释-2,变异和临床注释数据

瑞舒伐他汀

临床注释ID

981345350

药物名称(英)

rosuvastatin

变异单倍型

rs4149056

基因

SLCO1B1

证据级别

1A

水平覆盖

水平修饰符

Tier 1 VIP

表现型类别(英)

Metabolism/PK

表现型类别

代谢/PK

分数

114.125

PMID计数

13

计数的证据

16

表现型

高胆固醇血症

表现型(英)

Hypercholesterolemia

最新日期

2022/2/14 0:00:00

URL

https://www.pharmgkb.org/clinicalAnnotation/981345350

专业人口(英)

Pediatric

专业人口

儿科

临床等位基因

id	等位基因	注释文本
1153	TT	Patients with the rs4149056 TT genotype may have lower plasma concentrations of rosuvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and rosuvastatin and does not include evidence about clinical outcomes.
1152	CT	Patients with the rs4149056 CT genotype may have higher plasma concentrations of rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and rosuvastatin and does not include evidence about clinical outcomes.
1151	CC	Patients with the rs4149056 CC genotype may have higher plasma concentrations of rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and rosuvastatin and does not include evidence about clinical outcomes.

临床证据

id	证据的ID	总结
4462	982043801	SLCO1B1 15/15 is associated with decreased metabolism of rosuvastatin in healthy individuals as compared to SLCO1B1 37/37.
4461	982043792	SLCO1B1 15/15 is associated with decreased metabolism of rosuvastatin in healthy individuals as compared to SLCO1B1 1/1.
4460	982043808	SLCO1B1 15/15 is associated with decreased metabolism of rosuvastatin in healthy individuals as compared to SLCO1B1 37/15.
4459	1451226461	SLCO1B1 15/15 is associated with increased concentrations of rosuvastatin in healthy individuals as compared to SLCO1B1 1/1 + 1/15.
4458	1449733005	Genotype CC is associated with increased concentrations of rosuvastatin in healthy individuals as compared to genotypes CT + TT.
4457	1447989994	Genotype CT is associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype TT.
4456	1451141460	Genotypes CC + CT are associated with increased exposure to rosuvastatin in people with Diabetes Mellitus and Hypercholesterolemia as compared to genotype TT.
4455	1451124180	Genotypes CC + CT are associated with increased concentrations of rosuvastatin as compared to genotype TT.
4454	1444693880	Allele T is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele C.
4453	1184169599	Allele C is associated with increased plasma concentrations of rosuvastatin as compared to allele T.
4452	1183631263	Genotype TT is associated with decreased plasma concentrations of rosuvastatin when treated with rosuvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT.
4451	827827497	Genotype CC is associated with increased AUC (p=0.002) and Cmax (p=0.003) when exposed to rosuvastatin in healthy individuals as compared to genotype TT.
4450	1451358660	Genotypes CC + CT are associated with increased exposure to rosuvastatin in healthy individuals as compared to genotype TT.
4449	1451358200	Genotypes CC + CT are associated with increased concentrations of rosuvastatin in children with Hypercholesterolemia as compared to genotype TT.
4448	1451228580	Genotypes CC + CT are associated with increased concentrations of rosuvastatin as compared to genotype TT.
4447	PA166262321	Annotation of CPIC Guideline for rosuvastatin and ABCG2, SLCO1B1

临床病史

id	类型	评论
1651	Note	Second curator check
1650	Update	added guideline as evidence
1649	Update	CA score added as part of scoring system release. LOE assigned following curator review.
1648	Update	updated text
1647	Update	Added PMIDs 25673568, 32361904, 16198652, 31857620 and 29950617 to evidence. Changed CA to be on PK only. Edited phenotype descriptions. Changed LOE to 2A.
1646	Update	Updated OMB race to appropriate biogeographical group
1645	Update	Removed outdated race notes

最新招商产品更多>>